ReviewFrontiers in clinical diabetes and healthcare2025
GLP-1 agonists and exercise: the future of lifestyle prioritization.
Review in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Foods as Modulators of GLP-1 Secretion.Nutrients · 2026Review
- Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Review
- Sex-Specific Determinants of Physical Activity Among Korean Adults Using Weight-Control Medications: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- GLP-1 Use, Downstream Medical Spending, and Acute-Care Burden Among Adults with BMI-Defined Obesity: An Overlap-Weighted MEPS Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance.Healthcare (Basel, Switzerland) · 2026Review
- Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy.Journal of clinical medicine · 2026Review
- Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.International journal of molecular sciences · 2026Review
- The impact of glucagon-like peptide-1 receptor agonists on objective physical activity in adults: a systematic review and exploratory meta-analysis.International journal of obesity (2005) · 2026Review
- Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm.Reports (MDPI) · 2026Article
- Observational
- Exercise and physical activity interventions in type 2 diabetes mellitus.Frontiers in endocrinology · 2026Review
- Latest advances and controversies of exercise therapy in the management of type 2 diabetes.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification. However, long-term weight maintenance is more successful when exercise is included, as stopping GLP-1 therapy alone often leads to weight regain, while exercise helps preserve muscle mass and sustain weight loss. Combining GLP-1 receptor agonists with structured lifestyle changes, especially increased protein intake and strength training, can mitigate muscle loss and enhance overall outcomes. As a result, future obesity management is likely to prioritize integrated approaches that combine pharmacotherapy with lifestyle interventions, rather than replacing lifestyle changes with medication alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.